Fifth Third Bancorp
ITOS

Fifth Third Bancorp’s iTeos Therapeutics ITOS Stock Holding History

Fifth Third Bancorp’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-188
Closed -$2.06K – 2583
2023
Q3 		$2.06K Buy
+188
New +$2.4K ﹤0.01% 2375
2023
Q2 		– Sell
-25
Closed -$340 – 2690
2023
Q1 		$340 Sell
25
-107
-81% -$1.92K ﹤0.01% 2722
2022
Q4 		$2.58K Hold
132
– – ﹤0.01% 2384
2022
Q3 		$3K Hold
132
– – ﹤0.01% 2327
2022
Q2 		$3K Buy
+132
New +$3.13K ﹤0.01% 2358

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fifth Third Bancorp's ITOS Position: Q4 2023 in Review

Fifth Third Bancorp sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 188 shares — an estimated $2.06K sold.

Fifth Third Bancorp first reported a position in ITOS in Q2 2022 and held it in 5 quarters. The position peaked at $3K in Q3 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Fifth Third Bancorp reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Fifth Third Bancorp sold 188 iTeos Therapeutics shares in Q4 2023, an estimated $2.06K.
  • Fifth Third Bancorp first reported a position in iTeos Therapeutics in Q2 2022 and held it in 5 quarters.
  • Fifth Third Bancorp's iTeos Therapeutics position peaked at $3K in Q3 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Fifth Third Bancorp's 13F filing for Q4 2023, filed 19 Jan 2024.